110 Views | 49 Downloads
Maria Rosario Garcia Campelo, Tel.: +34-981178353; Fax: +34-981297790ma.rosario.garcia.campelo@sergas.es
Conceptualization, S.S.R., H.M.L., G.J.R. and M.M.; methodology, S.S.R., H.M.L., G.J.R. and M.M.; formal analysis, C.Z., H.M.L. and E.G.; investigation, M.R.G.C., C.Z., H.M.L., T.M.K., G.J.R., T.M., D.N., S.P. and P.A.J.; resources, M.R.G.C., C.Z., S.S.R., T.M.K., G.J.R., T.M., D.N., S.P. and P.A.J.; data curation, M.R.G.C., H.M.L. and E.G.; writing—review and editing, M.R.G.C., C.Z., S.S.R., H.M.L., T.M.K., G.J.R., T.M., D.N., E.G., M.M., S.P. and P.A.J.; supervision, C.Z., S.S.R., H.M.L. and M.M. All authors have read and agreed to the published version of the manuscript.
The authors would like to thank the patients, their families, and their caregivers; the EXCLAIM investigators and their team members at each study site; and colleagues from Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Amy Zannikos from Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Takeda Development Center Americas, Inc., Lexington, MA, USA, and complied with the Good Publication Practice (GPP) guidelines [16]. Teodor G. Paunescu (Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA) is acknowledged for editorial assistance.
Maria Rosario Garcia Campelo: Honoraria—Takeda, AstraZeneca, Roche, Pfizer, Bristol Myers Squibb, and Boehringer Ingelheim; speakers bureau and/or advisory role—Takeda, AstraZeneca, Roche, Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Novartis, and Merck, Sharp & Dohme; Caicun Zhou: Honoraria or advisory role—Lilly China, Sanofi, Boehringer Ingelheim, Roche, Merck, Sharp & Dohme, Qilu, Hengrui, Innovent Biologics, C-Stone, LUYE Pharma, TopAlliance Biosciences Inc., and Amoy Diagnostics; Suresh S. Ramalingam: Honoraria or advisory role—Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Lilly, Genentech/Roche, GlaxoSmithKline, and Takeda; research support to institution—Amgen, Advaxis, Bristol Myers Squibb, Genmab, AstraZeneca, and Takeda; Huamao M. Lin: Employment—Takeda; Tae Min Kim: Honoraria or advisory role—AstraZeneca, Boryung, F. Hoffmann-La Roche/Genentech, Janssen, Novartis, Regeneron, Sanofi, Takeda, and Yuhan; research funding outside this work—AstraZeneca–Korea Health Industry Development Institute; Gregory J. Riely: Travel—Merck, Sharp & Dohme; research funding—all to institution: Novartis, Genentech/Roche, Millennium, GlaxoSmithKline, Pfizer, Infinity Pharmaceuticals, ARIAD, Mirati Therapeutics, and Merck; Tarek Mekhail: Speakers bureau—AstraZeneca, Bristol Myers Squibb, Lilly, Merck, and Takeda; advisory role—AstraZeneca and Lilly; Danny Nguyen: Publication fees—Takeda; Erin Goodman: Employment—Takeda; Minal Mehta: Former employment—Takeda; Sanjay Popat: Research funding—all to institution: Boehringer Ingelheim, Epizyme, Bristol Myers Squibb, Clovis Oncology, Roche, Lilly, Daiichi Sankyo, Janssen, Turning Point Therapeutics, and Takeda; honoraria—Boehringer Ingelheim, AstraZeneca, Roche, Takeda, and Chugai Pharma; consulting or advisory role—Boehringer Ingelheim, Bayer, Beigene, Blueprint, Daiichi Sankyo, GlaxoSmithKline, Incyte, Janssen, Lilly, Merck, Takeda, Seattle Genetics, Turning Point Therapeutics, Xcovery, Roche, Novartis, Pfizer, AstraZeneca, Bristol Myers Squibb, Merck, Sharp & Dohme, Guardant Health, and AbbVie; Pasi A. Jänne: Consulting—Araxes Pharmaceuticals, ARIAD/Takeda, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Lilly, Loxo Oncology, Merrimack, Mirati Therapeutics, Pfizer, Roche, Novartis, Voronoi, Daiichi Sankyo, SFJ Pharmaceuticals, and Biocartis; research support—Astellas, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Lilly, and Puma Biotechnology; stock ownership—Gatekeeper and Loxo Oncology; postmarketing royalties from Dana-Farber Cancer Institute–owned patent on EGFR mutations licensed to LabCorp.